Published in Medical Letter on the CDC and FDA, December 29th, 2002
The complaint seeks an injunction prohibiting CMS from implementing certain provisions of the recently announced new rule that contains changes to the hospital outpatient prospective payment system.
Specifically, Amgen is disputing the legality of provisions that would result in a significant reduction in the reimbursement rate for Aranesp (darbepoetin alfa) for Medicare patients in the hospital outpatient setting,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.